Developing brain-penetrant antibodies and oligonucleotide therapeutics for central nervous system diseases through our proprietary BrainPortal Platform.
ChainGen Bio is a clinical-stage biotechnology company developing brain-penetrant antibodies and oligonucleotide therapeutics for central nervous system diseases, powered by our proprietary AI-designed BrainPortal Platform for blood-brain barrier transport. The platform is engineered to combine precision targeting, scalable manufacturability, and translational efficiency across both antibody and oligo-based modalities.
De novo designed, self-folding TfR1-binding peptides engineered for receptor-selective, luminal-to-abluminal transport across the BBB.
Composed entirely of natural amino acids, with scalable fermentation and strong stability. Compatible with both antibodies (Plug-and-Play) and siRNA payloads (ARC).
Among the smallest BBB shuttles at approximately 80 amino acids, supported by wholly owned IP and a demonstrated path from design to first-in-human evaluation.
The blood-brain barrier (BBB) is formed by tightly connected brain vascular endothelial cells that protect the central nervous system, but also limit therapeutic access to sites of disease. Transferrin receptor 1 (TfR1) functions as a natural iron-transport gateway at the BBB. Our BrainPortal constructs bind TfR1 on the brain endothelium and are transported across the barrier into brain tissue through receptor-mediated transcytosis, without relying on delivery through the choroid plexus or cerebrospinal fluid.
BrainPortal Plus (CD98HC) expands the platform beyond TfR1, with additional transporter programs targeting INSR and IGF1R currently in development.
A clinical-stage pipeline of brain-penetrant programs targeting amyloid-beta, CD20, alpha-synuclein, and undisclosed targets for Alzheimer's disease, multiple sclerosis, Parkinson's disease, and Huntington's disease.
Founded in 2022 by experienced scientists and operators with deep expertise spanning discovery, translational research, development, and clinical execution.
The passion, expertise, and scientific rigor of our team drive every breakthrough at ChainGen Bio
Selected conference posters and scientific publications from our team advancing brain-penetrant biotherapeutics.
We welcome partnership discussions, including licensing, co-development, and new research collaborations.
We are looking for mission-driven scientists who combine deep expertise with urgency, creativity, and scientific excellence. If you want to work in a highly focused environment with the opportunity to translate bold ideas into meaningful therapeutic impact, we would welcome hearing from you.
hr@chaingenbio.com